within Pharmacolibrary.Drugs.ATC.D;

model D10AD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 5.833333333333334e-07,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>D10AD02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Retinol, also known as vitamin A1, is a fat-soluble vitamin essential for vision, immune function, and cellular growth. It is used in dermatology for treating acne and skin aging, commonly as topical formulations. Oral or injectable forms are used for vitamin A deficiency, though not common in developed countries. Retinol is approved for use as a dietary supplement and in prescription products.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic models specific to dermatological or systemic use of retinol (ATC D10AD02) in humans with full parameters. Parameter estimates based on general vitamin A (retinol) pharmacokinetics in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Schmitt-Hoffmann, AH, et al., &amp; Kovacs, P (2012). Oral alitretinoin: a review of the clinical pharmacokinetics and pharmacodynamics. <i>Expert review of clinical pharmacology</i> 5(4) 373–388. DOI:<a href=&quot;https://doi.org/10.1586/ecp.12.26&quot;>10.1586/ecp.12.26</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22943117/&quot;>https://pubmed.ncbi.nlm.nih.gov/22943117</a></p></li><li><p>Peng, YM, et al., &amp; Meyskens, FL (1989). Pharmacokinetics of N-4-hydroxyphenyl-retinamide and the effect of its oral administration on plasma retinol concentrations in cancer patients. <i>International journal of cancer</i> 43(1) 22–26. DOI:<a href=&quot;https://doi.org/10.1002/ijc.2910430106&quot;>10.1002/ijc.2910430106</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2521335/&quot;>https://pubmed.ncbi.nlm.nih.gov/2521335</a></p></li><li><p>Garofoli, F, et al., &amp; Stronati, M (2018). Levels and effectiveness of oral retinol supplementation in VLBW preterm infants. <i>International journal of immunopathology and pharmacology</i> 32 2058738418820484–None. DOI:<a href=&quot;https://doi.org/10.1177/2058738418820484&quot;>10.1177/2058738418820484</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30897987/&quot;>https://pubmed.ncbi.nlm.nih.gov/30897987</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end D10AD02;
